Sutent

(Sunitinib)

ApprovedSmall molecule

Sunitinib is used to treat certain types of cancer, including kidney cancer and gastrointestinal tumors. It works by blocking proteins that help cancer cells grow and divide.[2] Sutent is currently approved and in use across 16 indications[4].[1]

Sutent is one of 362 small molecule programs targeting Glioma. It is currently in Approved.

Indications

382

Total Trials

Active Trials

361

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

GliomaActive, not recruiting

OsteosarcomaRecruiting

Thymic CarcinomaActive, not recruiting

MortalityActive, not recruiting

Neuroendocrine NeoplasmUnknown

Renal Cell CarcinomaCompleted

Mantle Cell LymphomaActive, not recruiting

Gastrointestinal Stromal TumorCompleted

Advanced Solid TumorsCompleted

Solid TumorsRecruiting

GliomaPreclinical

Active, not recruiting

OsteosarcomaPhase 2

Recruiting

Thymic CarcinomaPhase 2

Active, not recruiting

MortalityPreclinical

Active, not recruiting

Neuroendocrine NeoplasmPreclinical

Unknown

Renal Cell CarcinomaApproved

Completed

Mantle Cell LymphomaPreclinical

Active, not recruiting

Gastrointestinal Stromal TumorApproved

Completed

Advanced Solid TumorsPhase 2

Completed

Solid TumorsPhase 2

Recruiting

Showing 10 of 16 indications

Competition

Competitive Landscape

286 competitors in Advanced Solid Tumors

#DrugCompanyPhaseTrials

Sutent

Pfizer

Approved

3 2

Keytruda

Merck & Co.

Phase 2

47 3

Taxol

Teva

Phase 2

24 4

Opdivo

Bristol-Myers Squibb

Phase 2

18 5

Paraplatin

AAvyxa

Phase 2

31 6

Tecentriq

Roche

Phase 2

11 7

Taxotere

AAvyxa

Phase 2

23 8

Yervoy

Bristol-Myers Squibb

Phase 2

6 9

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Braftovi

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

N/ARecruiting

Treatment

NCT05751733

Phase 3Active, not recruiting

Renal Cell Carcinoma

NCT02811861

Q4 2027

Phase 2Recruiting

Trial

NCT02925234

Q4 2028

Phase 3Active, not recruiting

Advanced

NCT05734105

Clinical

Trials by Indication[1]

Renal Cell Carcinoma29 trials

Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.

Completed· Pfizer logo

Pfizer··NCT04033991·684 enrolled

Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma

Completed· Pfizer logo

Pfizer·Phase 4·NCT00706706·105 enrolled

Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma

Withdrawn·GGuru Sonpavde·Phase 2·NCT03035630

Show 26 more trials

A Study for Participants With Metastatic Renal Cell Carcinoma

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00709995·17 enrolled

Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02853331·861 enrolled

A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma

Completed· Roche logo

Roche·Phase 2·NCT01984242·305 enrolled

Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma

Completed·CCASI Pharmaceuticals, Inc.·Phase 2·NCT00444314·82 enrolled

Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma

Terminated·LLudwig Institute for Cancer Research·Phase 1·NCT00520533·8 enrolled

Study of Sunitinib Administered as 4/2 vs. 2/1 Schedule in Advanced Renal Cell Carcinoma (RCC)

Completed·—·Phase 2·NCT00570882·76 enrolled

A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma

Terminated·UUniversity Health Network, Toronto·Phase 2·NCT00480935·3 enrolled

Palliative Radiofrequency Ablation in Metastatic Renal Cell Carcinoma Patients

Completed·KKidney Cancer Research Bureau·Phase 1/2·NCT00891475·114 enrolled

Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC)

Withdrawn·AAndrea Harzstark·Phase 2·NCT01616186

Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma

Unknown status·YYamagata University·Phase 3·NCT01481870·120 enrolled

Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan)

Completed· Pfizer logo

Pfizer··NCT00716625·1,674 enrolled

Phase II Study of Anlotinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma（RCC）

Unknown status· Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 2·NCT02072031·133 enrolled

Molecular Determinants for Therapy Response on Renal Cell Carcinoma

Unknown status·HHeidelberg University·N/A·NCT02208128·4 enrolled

A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population

Terminated·Vvghtpe user·Phase 2·NCT02626754·13 enrolled

Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma

Unknown status·RRenJi Hospital·N/A·NCT05816642·500 enrolled

Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery

Terminated·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 3·NCT02535351·13 enrolled

Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma

Completed· Novartis logo

Novartis·Phase 3·NCT00720941·1,110 enrolled

Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma

Terminated·AAmsterdam UMC, location VUmc·Phase 2·NCT02071641·5 enrolled

Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma

Active, not recruiting· Eisai logo

Eisai·Phase 3·NCT02811861·1,069 enrolled

Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma

Completed· Novartis logo

Novartis·Phase 2·NCT00903175·471 enrolled

Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT01185366·73 enrolled

A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)

Completed· Roche logo

Roche·Phase 3·NCT02420821·915 enrolled

Epidemiological Study to Identify Prognosis and Predictive Biomarkers for Advanced or Metastatic Renal Cell Carcinoma

Completed·SSpanish Oncology Genito-Urinary Group··NCT03519542·62 enrolled

Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma

Completed· Novartis logo

Novartis·Phase 2·NCT01147822·367 enrolled

Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma

Completed·—·Phase 2·NCT01108445·131 enrolled

A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma

Terminated· Eli Lilly logo

Eli Lilly·Phase 2·NCT01391130·110 enrolled

Kidney Cancer22 trials

A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer

Completed·AAssociation Pour La Recherche des Thérapeutiques Innovantes en Cancérologie·Phase 2·NCT02960906·200 enrolled

Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT02761057·152 enrolled

Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00459875·24 enrolled

Show 19 more trials

Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery

Terminated·HHarry Drabkin·Phase 1·NCT00747305·17 enrolled

Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01243359·6 enrolled

Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00499135·25 enrolled

Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer

Terminated·—·N/A·NCT01740154·13 enrolled

Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer

Completed·OOHSU Knight Cancer Institute·Phase 2·NCT00425386·60 enrolled

Sunitinib Malate Before and After Surgery in Treating Patients With Previously Untreated Metastatic Kidney Cancer

Completed·—·Phase 2·NCT01024205·43 enrolled

Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01835158·157 enrolled

Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01664182·41 enrolled

Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery

Completed·RRoswell Park Cancer Institute·Phase 1·NCT01061411·16 enrolled

Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer

Completed·RRoswell Park Cancer Institute·N/A·NCT00849186·20 enrolled

Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer

Completed·—·Phase 2·NCT01158222·37 enrolled

Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer

Unknown status·—·Phase 2·NCT00717587·20 enrolled

Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00462982·8 enrolled

Sunitinib Malate in Treating Patients With Kidney Cancer

Completed·CCentre Antoine Lacassagne·N/A·NCT00943839·60 enrolled

Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain

Completed·IInstitut Claudius Regaud·Phase 2·NCT00814021·21 enrolled

Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer

Terminated·RRutgers, The State University of New Jersey·Phase 2·NCT00853125·10 enrolled

Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer

Completed· Pfizer logo

Pfizer·Phase 2·NCT00338884·120 enrolled

Sunitinib Before or After Surgery in Treating Patients With Metastatic Kidney Cancer

Unknown status·GGruppo Italiano Carcinoma Renale·Phase 2·NCT00626509·110 enrolled

Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer

Completed·—··NCT01026337·43 enrolled

Breast Cancer9 trials

Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer

Unknown status·IInstitut Català d'Oncologia·Phase 1/2·NCT00931450·70 enrolled

Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer

Terminated·UUniversity of California, San Francisco·Phase 1/2·NCT00616122·32 enrolled

Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer

Completed·UUniversity of Washington·Phase 2·NCT00513695·68 enrolled

Show 6 more trials

Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer

Completed·IIndiana University·N/A·NCT00656669·23 enrolled

Sunitinib in Treating Patients With Newly Diagnosed Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Completed·NNCIC Clinical Trials Group·Phase 2·NCT00482755·4 enrolled

Sunitinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer Who Have Tumor Cells in the Bone Marrow

Terminated·UUniversity of California, San Francisco·Phase 2·NCT00824538·13 enrolled

A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer

Completed· Pfizer logo

Pfizer·Phase 3·NCT00435409·442 enrolled

Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer

Completed· Pfizer logo

Pfizer·Phase 3·NCT00393939·594 enrolled

A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer

Terminated· Pfizer logo

Pfizer·Phase 1/2·NCT00417885·6 enrolled

Gastrointestinal Stromal Tumor6 trials

Role of Surgery in Patients With Focally Progressive Gastrointestinal Stromal Tumors (GISTs) After Imatinib Treatment

Unknown status·SShanghai Zhongshan Hospital·N/A·NCT03862768·92 enrolled

Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal Tumors

Terminated·VVanderbilt-Ingram Cancer Center·Phase 1·NCT00573404·6 enrolled

A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor

Completed· Pfizer logo

Pfizer·Phase 2·NCT01396148·6 enrolled

Show 3 more trials

Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor

Completed· Pfizer logo

Pfizer·Phase 4·NCT00793871·60 enrolled

Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors

Terminated· Pfizer logo

Pfizer·Phase 3·NCT00372567·69 enrolled

A Phase I/II Study of Sunitinib Malate (SU011248) In Patients With Gastrointestinal Stromal Tumor (GIST)

Completed· Pfizer logo

Pfizer·Phase 1/2·NCT00457743·36 enrolled

Gastric Cancer5 trials

An International Phase 2 Study Of SU011248 In Patients With Advanced / Metastatic Gastric Cancer Failing Chemotherapy

Completed· Pfizer logo

Pfizer·Phase 2·NCT00226811·78 enrolled

Study Of Sunitinib In Combination With Cisplatin And 5-Fluorouracil In Patients With Advanced Gastric Cancer

Completed· Pfizer logo

Pfizer·Phase 1·NCT00555672·34 enrolled

Efficacy and Safety of Sunitinib in Metastatic Gastric Cancer

Completed·JJohannes Gutenberg University Mainz·Phase 2·NCT00411151·52 enrolled

Show 2 more trials

Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer

Completed· Pfizer logo

Pfizer·Phase 1·NCT00555620·76 enrolled

Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer

Completed·SSamsung Medical Center·Phase 2·NCT03170180·66 enrolled

85 more indications

Patients With Advanced Solid Tumors5 trials

Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid Tumors

Terminated· Pfizer logo

Pfizer·Phase 1·NCT00729833·45 enrolled

Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors

Completed·TThe Netherlands Cancer Institute·Phase 1·NCT01286896·43 enrolled

A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors

Completed· Pfizer logo

Pfizer·Phase 1·NCT00528619·96 enrolled

Show 2 more trials

Study of Combination of Sirolimus and Sutent in Patients With Advanced Solid Tumors Non-Curable With Standard Therapy

Terminated·YYale University·Phase 1·NCT00402415·18 enrolled

Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00813423·40 enrolled

Liver Cancer5 trials

Chemoembolization of the Liver With or Without Sunitinib Malate in Treating Patients With Liver Cancer

Completed·FFederation Francophone de Cancerologie Digestive·Phase 2/3·NCT01164202·78 enrolled

Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer

Terminated·UUniversity of Washington·Phase 2·NCT00787787·41 enrolled

Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer

Terminated· Pfizer logo

Pfizer·Phase 3·NCT00699374·1,075 enrolled

Show 2 more trials

Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Completed·SSwiss Cancer Institute·Phase 2·NCT00514228·45 enrolled

Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Terminated·RRoswell Park Cancer Institute·Phase 2·NCT00524316·16 enrolled

Non-Small Cell Lung Cancer5 trials

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

Withdrawn·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00748163

Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00698815·130 enrolled

Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01306045·647 enrolled

Show 2 more trials

A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer

Completed· Pfizer logo

Pfizer·Phase 2·NCT00113516·84 enrolled

Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung Cancer

Completed· Pfizer logo

Pfizer·Phase 2·NCT00092001·111 enrolled

Treatment4 trials

Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST

Recruiting·XXiangya Hospital of Central South University·N/A·NCT05751733·258 enrolled

Treatment Patterns With Targeted Therapies In Mrcc In Sweden - A Retrospective Analysis Of Data From National Registries

Completed· Pfizer logo

Pfizer··NCT04669366·1,205 enrolled

A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib

Completed·ZZai Lab (Shanghai) Co., Ltd.·Phase 2·NCT04633122·108 enrolled

Show 1 more trial

Sunitinib Treatment on Tissue Sodium Accumulation (TSS2)

Completed·—··NCT04368546·6 enrolled

Small Cell Lung Cancer3 trials

Salvage Therapy With Sunitinib,Docetaxel and Platinum on Metastatic or Unresectable Non Small Cell Lung Cancer

Unknown status·TTaipei Medical University Hospital·Phase 2·NCT01019798·16 enrolled

Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00453154·156 enrolled

Sunitinib Malate in Treating Patients With Small Cell Lung Cancer

Terminated·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00953459·9 enrolled

Refractory Solid Tumors3 trials

Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors

Completed·SSamsung Medical Center·Phase 4·NCT02691793·1 enrolled

Sunitinib in Treating Young Patients With Refractory Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00387920·35 enrolled

Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors

Completed·SSamsung Medical Center·N/A·NCT02450123·1 enrolled

Trial3 trials

The Drug Rediscovery Protocol (DRUP Trial)

Recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT02925234·1,550 enrolled

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Terminated·OOHSU Knight Cancer Institute·Phase 1·NCT03878524·2 enrolled

A Phase I Trial of Bortezomib and Sunitinib

Completed·EEmory University·Phase 1·NCT00720148·30 enrolled

Pancreatic Neuroendocrine Tumor3 trials

Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

Completed· Pfizer logo

Pfizer·Phase 2·NCT01121562·12 enrolled

The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors

Completed· Pfizer logo

Pfizer··NCT02282059·100 enrolled

A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

Completed· Pfizer logo

Pfizer·Phase 4·NCT01525550·106 enrolled

Efficacy and Safety3 trials

Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer

Completed·SShanghai Junshi Bioscience Co., Ltd.·Phase 3·NCT04394975·421 enrolled

A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer

Completed· Pfizer logo

Pfizer·Phase 3·NCT00375674·674 enrolled

A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine

Terminated· Pfizer logo

Pfizer·Phase 3·NCT00373113·482 enrolled

Metastatic Renal Cell Cancer3 trials

Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC)

Completed· Pfizer logo

Pfizer·Phase 2·NCT00267748·317 enrolled

A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R)

Terminated· Roche logo

Roche·Phase 2·NCT00491738·16 enrolled

A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT01829841·150 enrolled

Cancer3 trials

Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00890747·42 enrolled

OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults

Unknown status·UUniversity Medical Center Groningen·Phase 4·NCT05949424·30 enrolled

The Influence of Phenotype, Grapefruit Juice and Orange Juice on the Pharmacokinetics of Sunitinib in Cancer Patients

Completed·LLeiden University Medical Center·Phase 1·NCT01743300·15 enrolled

Unresectable2 trials

Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST

Completed·—·Phase 1·NCT02164240·14 enrolled

Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II

Completed·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT02230176·84 enrolled

Advanced Cancers2 trials

Interaction Study of Rapamycin and Sunitinib in Patients With Advanced Cancers

Completed·UUniversity of Chicago·Phase 1·NCT00583063·23 enrolled

Perifosine + Sunitinib Malate for Patients With Advanced Cancers

Completed·AAEterna Zentaris·Phase 1·NCT00399152·15 enrolled

Malignant Glioma2 trials

Sunitinib in Treating Patients With Recurrent Malignant Gliomas

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00499473·31 enrolled

Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01462695·30 enrolled

Bladder Cancer2 trials

Sunitinib in Treating Patients With Locally Advanced Bladder Cancer

Completed·—·Phase 2·NCT00526656·9 enrolled

Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer

Terminated·—·Phase 2·NCT01118351·19 enrolled

Esophageal Cancer2 trials

Sutent + Taxol for Advanced Esophageal Cancer

Completed·HHoosier Cancer Research Network·Phase 2·NCT00730353·28 enrolled

Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer

Terminated·RRoswell Park Cancer Institute·Phase 1·NCT00524186·23 enrolled

Soft Tissue Sarcoma2 trials

Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00400569·48 enrolled

Sunitinib and Radiation in Patients With Resectable Soft-tissue Sarcoma

Unknown status·AAustralasian Sarcoma Study Group·Phase 1/2·NCT00753727·26 enrolled

Patients With Solid Tumors2 trials

Bevacizumab and Sunitinib in Treating Patients With Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00357318·60 enrolled

Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors

Completed· Pfizer logo

Pfizer·Phase 1·NCT00599924·53 enrolled

Pancreatic Cancer2 trials

Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00462553·37 enrolled

Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00397787·64 enrolled

Metastatic Colorectal Cancer2 trials

FOLFIRI and Sunitinib in Metastatic Colorectal Cancer

Completed·CCentral European Society for Anticancer Drug Research·Phase 2·NCT00806663·22 enrolled

Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer

Completed· Pfizer logo

Pfizer·Phase 3·NCT00457691·768 enrolled

Prostate Cancer2 trials

Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients

Terminated·JJohn P. Fruehauf·Phase 1/2·NCT00879619·4 enrolled

Study of Sunitinib Malate in Patients With Newly Diagnosed Prostate Cancer Prior to Prostatectomy

Completed·—·Phase 2·NCT00672594·30 enrolled

Melanoma2 trials

Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma

Completed·JJonsson Comprehensive Cancer Center·Phase 1·NCT01005472·16 enrolled

Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma

Terminated·NNational Institutes of Health Clinical Center (CC)·Phase 2·NCT00482911·12 enrolled

Metastatic2 trials

Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00397488·78 enrolled

Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC

Terminated·TThe Methodist Hospital Research Institute·Phase 1/2·NCT00522249·10 enrolled

Germ Cell Tumor2 trials

Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00453310·10 enrolled

Sunitinib Malate in Refractory Germ Cell Tumors

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00912912·5 enrolled

Mortality1 trial

OPALINE : A Study Of Morbidity And Mortality At 2 Years

Completed· Pfizer logo

Pfizer··NCT02264665·144 enrolled

First Line Therapy1 trial

Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer

Completed·UUNICANCER·Phase 2·NCT00541008·92 enrolled

Malignant Pleural Mesothelioma1 trial

Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00392444·39 enrolled

Kaposi Sarcoma1 trial

Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT00521092

Ovarian Clear Cell Carcinoma1 trial

Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma

Completed·—·Phase 2·NCT01824615·30 enrolled

Peritoneal Carcinoma1 trial

Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma

Completed·—·Phase 2·NCT00768144·36 enrolled

Ascites1 trial

Trial of Sunitinib for Refractory Malignant Ascites

Terminated·MMilton S. Hershey Medical Center·Phase 2·NCT00796861·4 enrolled

Bevacizumab1 trial

Bevacizumab in Multiple Phase I Combinations

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00543504·343 enrolled

Glioma1 trial

HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors)

Unknown status·AAmsterdam UMC, location VUmc·N/A·NCT02239952·15 enrolled

Neuroendocrine Tumors1 trial

Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT02315625·16 enrolled

Glioblastoma Multiforme1 trial

SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme

Unknown status·MMedical University Innsbruck·Phase 2·NCT00535379·70 enrolled

Completed·CCogent Biosciences, Inc.·Phase 1/2·NCT02401815·51 enrolled

Colorectal Carcinoma1 trial

Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC)

Unknown status·AAmsterdam UMC, location VUmc·Phase 2/3·NCT03909724·60 enrolled

Urinary Tract Cancer1 trial

Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer

Unknown status·—·Phase 2·NCT01118039·41 enrolled

Multiple Myeloma1 trial

Sunitinib in Treating Patients With Relapsed Multiple Myeloma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00514137·13 enrolled

Colorectal Cancer1 trial

Study Of Sunitinib In Combination With Folfox In Patients With Colorectal Cancer

Completed· Pfizer logo

Pfizer·Phase 1·NCT00631410·12 enrolled

Hepatocellular Cancer1 trial

Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC)

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00495625·33 enrolled

Anaplastic Astrocytoma1 trial

A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00606008·30 enrolled

Second-line Therapy1 trial

Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer

Completed·IInstitut Curie·Phase 2·NCT00792025·80 enrolled

Ocular Melanoma1 trial

Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma

Unknown status·SSan Diego Pacific Oncology & Hematology Associates·Phase 2·NCT00489944·50 enrolled

Metastatic Cancer1 trial

Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer

Completed·IIcahn School of Medicine at Mount Sinai·Phase 1/2·NCT00463060·47 enrolled

Thyroid Cancer1 trial

Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer

Completed·UUniversity of Washington·Phase 2·NCT00519896·35 enrolled

Cervical Cancer1 trial

Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00389974·19 enrolled

Chronic Myelomonocytic Leukemia1 trial

Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00451048·10 enrolled

Primary Peritoneal Cancer1 trial

Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00388037·31 enrolled

Lip1 trial

Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients

Terminated· Pfizer logo

Pfizer··NCT01073644·3 enrolled

Metastatic Head and Neck Cancer1 trial

Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00387335·22 enrolled

Squamous Cell Carcinoma1 trial

Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00906360·36 enrolled

Transitional Cell Carcinoma1 trial

Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)

Completed·—·Phase 2·NCT01089088·63 enrolled

Phase II1 trial

Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00434109·39 enrolled

Leiomyosarcoma1 trial

Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00378911·44 enrolled

Ovarian Cancer1 trial

Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00979992·35 enrolled

Endometrial Cancer1 trial

Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00478426·34 enrolled

Islet Cell Tumor1 trial

A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors

Terminated· Pfizer logo

Pfizer·Phase 3·NCT00428597·171 enrolled

Safety and Efficacy1 trial

Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene

Completed· Pfizer logo

Pfizer··NCT00444795·520 enrolled

Lymphoma1 trial

Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00392496·19 enrolled

Myelofibrosis1 trial

Sunitinib in Treating Patients With Idiopathic Myelofibrosis

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00387426·14 enrolled

Brain Metastases1 trial

Sunitinib Malate After Stereotactic Radiosurgery in Treating Patients With Newly Diagnosed Brain Metastases

Terminated·—·Phase 2·NCT00910039·14 enrolled

Gemcitabine1 trial

Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC

Terminated·NNoah Hahn, M.D.·Phase 2·NCT00859339·9 enrolled

Recurrent Sarcoma1 trial

Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00474994·53 enrolled

Acute Lymphoblastic Leukemia1 trial

Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

Completed·OOHSU Knight Cancer Institute·Phase 1·NCT02779283·7 enrolled

Eye Disease1 trial

Sunitinib Malate to Treat Advanced Eye Disease in Patients With Von Hippel-Lindau Syndrome

Terminated·NNational Eye Institute (NEI)·Phase 1/2·NCT00673816·2 enrolled

Ebola Virus Disease1 trial

Multiple Treatments for Ebola Virus Disease (EVD)

Unknown status·CClinical Research Management, Inc.·Phase 1/2·NCT02380625·150 enrolled

Bone Sarcoma1 trial

Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas

Completed·GGrupo Espanol de Investigacion en Sarcomas·Phase 1/2·NCT03277924·197 enrolled

Chronic Lymphocytic Leukemia1 trial

Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00398112·18 enrolled

GIST1 trial

Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan).

Completed· Pfizer logo

Pfizer··NCT00716820·472 enrolled

Gastroesophageal Junction Cancer1 trial

Sunitinib in Treating Patients With Relapsed or Refractory Esophageal or Gastroesophageal Junction Cancer

Completed·TTony Bekaii-Saab·Phase 2·NCT00702884·25 enrolled

Nasopharyngeal Carcinoma1 trial

Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)

Completed·NNational University Hospital, Singapore·Phase 2·NCT01309633·80 enrolled

Colon Cancer1 trial

Sunitinib and Capecitabine for First Line Colon Cancer

Terminated·GGeorgetown University·Phase 2·NCT00961571·50 enrolled

Rectal Cancer1 trial

Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery

Withdrawn·FFederation Francophone de Cancerologie Digestive·Phase 2·NCT00936832

Tumour1 trial

Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib

Completed·AAB Science·Phase 2·NCT01506336·44 enrolled

Effectiveness1 trial

Cost Effectiveness Of Sunitinib In Central America And Caribbean

Terminated· Pfizer logo

Pfizer··NCT01033981·4 enrolled

Advanced Cancer1 trial

Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer

Completed· Pfizer logo

Pfizer·Phase 1·NCT00712504·49 enrolled

Chemotherapy1 trial

Clinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 Years

Completed·UUniversitätsklinikum Hamburg-Eppendorf·Phase 1/2·NCT00783653·22 enrolled

Clear Cell Renal Cancer1 trial

Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer

Terminated·AAssociació per a la Recerca Oncologica, Spain·Phase 2·NCT01784978·41 enrolled

Metastatic Melanoma1 trial

Trial of Single Agent Sunitinib for Patients With Chemo-refractory Metastatic Melanoma

Terminated·KKrankenhaus Nordwest·Phase 2·NCT01216657·7 enrolled

Dacarbazine1 trial

A Phase I/II Study of Sunitinib and Dacarbazine

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT00496223·11 enrolled

Advanced1 trial

A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib

Active, not recruiting·DDeciphera Pharmaceuticals, LLC·Phase 3·NCT05734105·54 enrolled

Unspecified3 trials

Study of Sunitinib in Patients With Von Hippel-Lindau (VHL) Disease

Completed·AAssociation Pour La Recherche des Thérapeutiques Innovantes en Cancérologie·Phase 2·NCT01168440·5 enrolled

A Bioequivalence Study of Sunitinib Malate Capsules.

Completed· Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1·NCT05800106·24 enrolled

Rollover Protocol for Prior SU011248 Protocols

Completed· Pfizer logo

Pfizer·N/A·NCT00798889·314 enrolled

Regulatory

FDA Approval Timeline[5]

May 10, 2006

SUTENT

NDA NDA021938

Feb 2, 2007

SUTENT

NDA NDA021938

Feb 2, 2007

SUTENT

NDA NDA021938

Feb 2, 2007

SUTENT

NDA NDA021938

Feb 2, 2007

SUTENT

NDA NDA021938

Nov 7, 2008

SUTENT

NDA NDA021938

Nov 7, 2008

SUTENT

NDA NDA021938

Nov 7, 2008

SUTENT

NDA NDA021938

Mar 31, 2009

SUTENT

NDA NDA021938

Jul 1, 2010

SUTENT

NDA NDA021938

Jul 1, 2010

SUTENT

NDA NDA021938

Jul 1, 2010

SUTENT

NDA NDA021938

Jul 1, 2010

SUTENT

NDA NDA021938

May 20, 2011

SUTENT

NDA NDA021938

May 20, 2011

SUTENT

NDA NDA021938

May 20, 2011

SUTENT

NDA NDA021938

Apr 20, 2012

SUTENT

NDA NDA021938

Apr 20, 2012

SUTENT

NDA NDA021938

Nov 16, 2012

SUTENT

NDA NDA021938

Nov 16, 2012

SUTENT

NDA NDA021938

Nov 16, 2012

SUTENT

NDA NDA021938

Aug 30, 2013

SUTENT

NDA NDA021938

Aug 30, 2013

SUTENT

NDA NDA021938

Jun 11, 2014

SUTENT

NDA NDA021938

Dec 19, 2014

SUTENT

NDA NDA021938

Apr 24, 2015

SUTENT

NDA NDA021938

Apr 24, 2015

SUTENT

NDA NDA021938

Oct 8, 2015

SUTENT

NDA NDA021938

Nov 16, 2015

SUTENT

NDA NDA021938

Nov 16, 2017

SUTENT

NDA NDA021938

Dec 13, 2018

SUTENT

NDA NDA021938

May 7, 2019

SUTENT

NDA NDA021938

Jul 10, 2020

SUTENT

NDA NDA021938

Aug 14, 2020

SUTENT

NDA NDA021938

Aug 30, 2021

SUTENT

NDA NDA021938

Sources

References

[1]
ClinicalTrials.gov — 382 trial records for Sunitinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Sutent drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Sunitinib compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Sunitinib. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA021938). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Macrophage Colony Stimulating Factor Receptor Inhibitor; Stem Cell Growth Factor Receptor Inhibitor; Vascular Endothelial Growth Factor Receptor 1 Inhibitor; Vascular Endothelial Growth Factor Receptor 2 Inhibitor; Vascular Endothelial Growth Factor Receptor Inhibitor; Platelet-Derived Growth Factor Receptor Alpha Inhibitor; Platelet-Derived Growth Factor Receptor Beta Inhibitor; Platelet-Derived Growth Factor Receptor Inhibitor; Tyrosine-Protein Kinase Receptor FLT3 Inhibitor; Tyrosine-Protein Kinase Receptor RET Inhibitor; Vascular Endothelial Growth Factor Receptor 3 Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Pfizer

Sutent

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2027

Q4 2028

Trials by Indication[1]

Renal Cell Carcinoma29 trials

Kidney Cancer22 trials

Breast Cancer9 trials

Gastrointestinal Stromal Tumor6 trials

Gastric Cancer5 trials

Patients With Advanced Solid Tumors5 trials

Liver Cancer5 trials

Non-Small Cell Lung Cancer5 trials

Treatment4 trials

Small Cell Lung Cancer3 trials

Refractory Solid Tumors3 trials

Trial3 trials

Pancreatic Neuroendocrine Tumor3 trials

Efficacy and Safety3 trials

Metastatic Renal Cell Cancer3 trials

Cancer3 trials

Unresectable2 trials

Advanced Cancers2 trials

Malignant Glioma2 trials

Bladder Cancer2 trials

Esophageal Cancer2 trials

Soft Tissue Sarcoma2 trials

Patients With Solid Tumors2 trials

Pancreatic Cancer2 trials

Metastatic Colorectal Cancer2 trials

Prostate Cancer2 trials

Melanoma2 trials

Metastatic2 trials

Germ Cell Tumor2 trials

Mortality1 trial

First Line Therapy1 trial

Malignant Pleural Mesothelioma1 trial

Kaposi Sarcoma1 trial

Ovarian Clear Cell Carcinoma1 trial

Peritoneal Carcinoma1 trial

Ascites1 trial

Bevacizumab1 trial

Glioma1 trial

Neuroendocrine Tumors1 trial

Glioblastoma Multiforme1 trial

Cholangiocarcinoma1 trial

Thymic Carcinoma1 trial

Advanced Solid Tumors1 trial

Colorectal Carcinoma1 trial

Urinary Tract Cancer1 trial

Multiple Myeloma1 trial

Colorectal Cancer1 trial

Hepatocellular Cancer1 trial

Anaplastic Astrocytoma1 trial

Second-line Therapy1 trial

Ocular Melanoma1 trial

Metastatic Cancer1 trial

Thyroid Cancer1 trial

Cervical Cancer1 trial

Chronic Myelomonocytic Leukemia1 trial

Primary Peritoneal Cancer1 trial

Lip1 trial

Metastatic Head and Neck Cancer1 trial

Squamous Cell Carcinoma1 trial

Transitional Cell Carcinoma1 trial

Phase II1 trial

Leiomyosarcoma1 trial

Ovarian Cancer1 trial

Endometrial Cancer1 trial

Islet Cell Tumor1 trial

Safety and Efficacy1 trial

Lymphoma1 trial

Myelofibrosis1 trial

Brain Metastases1 trial

Gemcitabine1 trial

Recurrent Sarcoma1 trial

Acute Lymphoblastic Leukemia1 trial